Collegium Pharmaceutical (COLL) Stock Analysis 2026: Specialty Pharma at 4.6x Forward Earnings, 57% Analyst Upside — May 14 Earnings

Price: $34.41 | Sector: Pharmaceuticals | Earnings: May 14, 2026

At 4.57x forward earnings, Collegium Pharmaceutical carries one of the lowest forward P/E multiples of any stock in the Equity Rank screener. The company generates $830M in annual revenue, grows at 12.9%, earns a zero Merton default probability, and commands a $54.17 analyst consensus target — 57% above the current price. The EV/EBITDA fair value is $168.34, suggesting the operational cash flows are priced at a fraction of sector-comparable multiples.

The discount is not mysterious: Collegium's products are opioids, and the opioid litigation risk premium is real and persistent. The question the model poses is whether the market has overshot — pricing in catastrophic outcomes for a company that has carefully positioned itself in the legally and therapeutically distinct corner of the pain management market.

What Collegium Pharmaceutical Does

Collegium Pharmaceutical, Inc. (Nasdaq: COLL) is a specialty pharmaceutical company focused on responsible pain management. Headquartered in Stoughton, Massachusetts, its commercial portfolio centers on two key products:

Xtampza ER (oxycodone myristate, extended-release capsules): An abuse-deterrent formulation of oxycodone designed to be more resistant to crushing, cutting, and dissolution — the primary routes of abuse for traditional oxycodone tablets. Its FDA-approved abuse-deterrent label distinguishes it from generic oxycodone ER products, providing a formulary positioning advantage with pharmacy benefit managers and managed care payers. Xtampza ER holds patent protection that currently deters generic competition.

Belbuca (buprenorphine buccal film): A Schedule III buccal film delivery of buprenorphine, a partial mu-opioid agonist. Because buprenorphine has a ceiling effect on respiratory depression, it carries meaningfully lower overdose risk than full agonist opioids. Its Schedule III classification (vs. Schedule II for most opioids) provides prescribing and formulary advantages. Belbuca is FDA-approved for chronic pain requiring daily opioid therapy.

Collegium's strategic positioning — abuse-deterrent and lower-risk opioid formulations — is a deliberate attempt to occupy a different legal and clinical space than the products at the center of the national opioid litigation. Whether courts ultimately distinguish Collegium's products from legacy oxycodone manufacturers remains the key risk question.

Revenue is growing at 12.9% TTM. Current-year estimates point to $831M with $881M projected for the following year.

Equity Rank Score: 75.2

Key scorecard inputs from the model:

• Combined Margin of Safety: 62.6%
• Risk Score: 42 (moderate)
• Forward P/E: 4.57x | Trailing P/E: 19.89x
• Forward EPS: $2.275 (analyst consensus)
• Trailing EPS: $1.73
• Revenue Growth: 12.9% TTM
• Merton Default Probability: 0% | Distance to Default: 11.28
• Sector Bubble Score: 40 (slightly elevated, 16.7% premium applied)
• Data Quality: partial (DCF/P/FCF excluded as outliers)

The forward PE of 4.57x is the central number. The pharma sector median forward PE is approximately 15–18x. At 15x on $2.275 forward EPS, implied price is ~$34 — essentially the current price. The stock is already priced at the sector median on trailing earnings and well below it on forward earnings. Every PE multiple above 6x represents upside to the current price.

The Valuation Picture

Consensus Fair Value: $65.16 | Consensus MoS: 47.2% Analyst Consensus Target: $54.17 (+57.4% upside)

The EV/EBITDA fair value of $168.34 is the most striking output. It indicates that at pharmaceutical sector-median EV/EBITDA multiples, the business would be worth roughly 5x its current stock price. The entire gap between $168 and $34 represents the litigation/competition risk premium baked in by the market.

The EPV of $66.73 (48.4% MoS) is important because it requires no growth — only current earnings power discounted at cost of capital. A stock trading below its no-growth EPV is inexpensive even in a stagnation scenario.

The Graham Number at $19.04 is far below the current price, meaning the most conservative balance-sheet method shows no margin of safety. The thesis is entirely earnings-power dependent — the value comes from the cash flow and EBITDA multiples, not from assets.

Why It Trades at 4.57x Forward Earnings

Opioid litigation risk: The national opioid litigation wave has extracted billions from manufacturers and distributors. While Collegium's abuse-deterrent positioning distinguishes it, the company faces ongoing opioid-related litigation at various jurisdictional levels. Adverse outcomes could be materially damaging. The litigation risk is genuinely difficult to quantify — this is the dominant discount driver.

Abuse-deterrent distinction: Collegium argues its products reduce abuse potential compared to legacy formulations. FDA's abuse-deterrent labeling and Belbuca's Schedule III status provide regulatory support for this distinction. Courts have varied in how much weight they assign to product formulation in apportioning opioid liability.

Generic competition: Xtampza ER's patent protection is finite. When generic abuse-deterrent oxycodone becomes commercially viable, Collegium's pricing power and market share face structural pressure. The uncertainty around the patent expiration timeline is reflected in the DCF's "outlier" exclusion.

Single-specialty concentration: The portfolio is concentrated in two pain-management products. Any adverse formulary decision, payer restriction, or prescribing guideline change could rapidly affect revenue.

Revenue and Earnings Trajectory

EPS growth from $1.73 (trailing) to $2.275 (forward) represents 31.5% year-over-year growth. This is the mechanical driver of the low forward PE — earnings are growing faster than the stock has moved. If the $2.275 forward estimate is achieved, Collegium will generate approximately 6.6% of its current market cap in net income annually.

Analyst consensus target of $54.17 with meaningful sell-side conviction (the majority of covering analysts are bullish) reflects a detailed, company-specific view of the litigation risk that arrives at +57% upside from current levels. This is not a consensus anchored to the current price — it reflects genuine fundamental upside assessment.

What May 14 Earnings Will Show

Collegium reports Q1 2026 results on May 14, 2026. Key metrics:

• Net revenue — continuation of 12.9% growth trajectory or deceleration?
• Xtampza ER vs. Belbuca revenue split — which product is driving growth?
• Adjusted EBITDA margin — does operational leverage continue to build?
• Litigation updates — any new settlements, judgments, or dismissals
• FY2026 guidance — management's formal revenue and earnings outlook

A quarter that confirms the earnings growth trajectory and provides no adverse litigation news would challenge the 4.57x multiple's implicit assumption of deterioration.

Equity Rank Tools for COLL Analysis

The P/E Ratio Calculator makes the multiple-expansion thesis quantitative. Input forward EPS of $2.275: at 8x the price is ~$18, at 12x it's ~$27, at 15x it's ~$34 (current), at 20x it's ~$46, at 25x it's ~$57 (near analyst target). The range of outcomes under different PE normalization assumptions shows the potential upside if litigation risk fades.

The EV/EBITDA Calculator tests the operational value thesis. The $168.34 EV/EBITDA fair value vs. $34.41 current price shows what multiple the market is currently applying to Collegium's EBITDA — and what multiple expansion toward sector peers would imply for the equity price.

The Intrinsic Value Calculator runs all eight methods simultaneously. For COLL, the EPV at $66.73 is the most important output — it confirms the stock is undervalued even on a zero-growth, earnings-only basis, before any assumption about revenue or EPS growth.

The Margin of Safety Calculator allows you to apply your own litigation risk haircut to the consensus. If you believe litigation represents a 30% permanent haircut to intrinsic value ($65 — 0.7 = $45.50), what entry price gives you a 20% MoS on that risk-adjusted estimate? This personalizes the thesis to your own risk tolerance and uncertainty level.

This article is for informational and educational purposes only. It does not constitute financial advice or a recommendation to purchase or sell Collegium Pharmaceutical, Inc. (COLL) shares or any other security. All scores, margin of safety estimates, and valuation outputs are model-based and subject to significant estimation uncertainty. The forward P/E of 4.57x is based on the analyst consensus forward EPS estimate of $2.275; actual results may differ materially. The consensus fair value of $65.16 is driven primarily by EV/EBITDA and P/S methods applying sector-median multiples; if the litigation discount persists, these estimates may not be realized within any particular time frame. The EV/EBITDA fair value of $168.34 reflects pharmaceutical sector EV/EBITDA comparables and is a sector-relative reference, not a price target; Collegium's actual multiple depends on how investors classify its specific risk profile. The Graham Number of $19.04 is far below the current price — no balance-sheet margin of safety exists; the thesis depends entirely on earnings power and FCF multiples. Opioid litigation risk is material, ongoing, and not fully quantifiable; adverse legal outcomes could result in settlements or judgments that materially impair the business and stock. Collegium's abuse-deterrent product positioning may or may not reduce its litigation exposure — courts have varied in how they weigh this distinction. Patent protection timelines for Xtampza ER are finite; generic competition upon expiration would pressure revenue and margins. Revenue growth of 12.9% is trailing and may not be sustained. Data quality is classified as partial — DCF and P/FCF are excluded as outliers, limiting valuation cross-checks. The analyst consensus target of $54.17 reflects analyst views that may not account for all relevant litigation scenarios and may change. Merton distance to default of 11.28 is lower than other names in this series, indicating moderately elevated financial stress risk relative to investment-grade peers; investors should review the balance sheet before forming conclusions. The May 14, 2026 earnings report may move the stock materially. All investments involve risk, including potential loss of principal. Equity Rank is not a registered investment adviser. Always conduct your own due diligence and consult a qualified financial adviser before making investment decisions.